Sheaff Brock Investment Advisors LLC Has $531,000 Position in Aratana Therapeutics Inc (PETX)

Sheaff Brock Investment Advisors LLC increased its position in Aratana Therapeutics Inc (NASDAQ:PETX) by 42.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 101,000 shares of the biopharmaceutical company’s stock after buying an additional 30,000 shares during the quarter. Sheaff Brock Investment Advisors LLC owned 0.23% of Aratana Therapeutics worth $531,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Teachers Advisors LLC increased its stake in shares of Aratana Therapeutics by 34.5% in the second quarter. Teachers Advisors LLC now owns 72,244 shares of the biopharmaceutical company’s stock worth $522,000 after buying an additional 18,526 shares during the period. Nationwide Fund Advisors increased its stake in shares of Aratana Therapeutics by 50.0% in the second quarter. Nationwide Fund Advisors now owns 78,383 shares of the biopharmaceutical company’s stock worth $567,000 after buying an additional 26,130 shares during the period. Wells Fargo & Company MN increased its stake in shares of Aratana Therapeutics by 20.8% in the third quarter. Wells Fargo & Company MN now owns 367,365 shares of the biopharmaceutical company’s stock worth $2,252,000 after buying an additional 63,377 shares during the period. State Street Corp increased its stake in shares of Aratana Therapeutics by 10.2% in the second quarter. State Street Corp now owns 597,180 shares of the biopharmaceutical company’s stock worth $4,317,000 after buying an additional 55,480 shares during the period. Finally, Alyeska Investment Group L.P. increased its stake in shares of Aratana Therapeutics by 10.5% in the third quarter. Alyeska Investment Group L.P. now owns 964,116 shares of the biopharmaceutical company’s stock worth $5,910,000 after buying an additional 91,763 shares during the period. 71.06% of the stock is currently owned by institutional investors.

In other news, insider Craig A. Tooman sold 30,000 shares of the business’s stock in a transaction on Thursday, January 11th. The shares were sold at an average price of $5.27, for a total transaction of $158,100.00. Following the sale, the insider now owns 75,024 shares in the company, valued at approximately $395,376.48. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Peter Steven St sold 19,367 shares of the business’s stock in a transaction on Tuesday, January 30th. The shares were sold at an average price of $4.77, for a total transaction of $92,380.59. Following the sale, the chief executive officer now owns 672,259 shares in the company, valued at approximately $3,206,675.43. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,056,399 shares of company stock worth $6,087,271. Insiders own 5.20% of the company’s stock.

A number of research analysts have issued reports on PETX shares. Zacks Investment Research downgraded shares of Aratana Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, January 17th. Jefferies Group set a $9.00 price objective on shares of Aratana Therapeutics and gave the company a “buy” rating in a research report on Thursday, November 16th. ValuEngine downgraded shares of Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st. CL King started coverage on shares of Aratana Therapeutics in a research report on Wednesday, December 27th. They set a “neutral” rating on the stock. Finally, HC Wainwright set a $10.00 price objective on shares of Aratana Therapeutics and gave the company a “buy” rating in a research report on Tuesday, January 16th. Three investment analysts have rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $8.55.

Aratana Therapeutics Inc (NASDAQ PETX) opened at $4.09 on Friday. The company has a current ratio of 3.42, a quick ratio of 3.08 and a debt-to-equity ratio of 0.26. The stock has a market cap of $178.04, a price-to-earnings ratio of -2.82 and a beta of 3.06. Aratana Therapeutics Inc has a 1 year low of $3.91 and a 1 year high of $7.67.

ILLEGAL ACTIVITY WARNING: “Sheaff Brock Investment Advisors LLC Has $531,000 Position in Aratana Therapeutics Inc (PETX)” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/24/sheaff-brock-investment-advisors-llc-has-531000-position-in-aratana-therapeutics-inc-petx.html.

About Aratana Therapeutics

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Want to see what other hedge funds are holding PETX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aratana Therapeutics Inc (NASDAQ:PETX).

Institutional Ownership by Quarter for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply